Nature Communications (Feb 2018)
Tuning microtubule dynamics to enhance cancer therapy by modulating FER-mediated CRMP2 phosphorylation
- Yiyan Zheng,
- Ritika Sethi,
- Lingegowda S. Mangala,
- Charlotte Taylor,
- Juliet Goldsmith,
- Ming Wang,
- Kenta Masuda,
- Mohammad Karaminejadranjbar,
- David Mannion,
- Fabrizio Miranda,
- Sandra Herrero-Gonzalez,
- Karin Hellner,
- Fiona Chen,
- Abdulkhaliq Alsaadi,
- Ashwag Albukhari,
- Donatien Chedom Fotso,
- Christopher Yau,
- Dahai Jiang,
- Sunila Pradeep,
- Cristian Rodriguez-Aguayo,
- Gabriel Lopez-Berestein,
- Stefan Knapp,
- Nathanael S. Gray,
- Leticia Campo,
- Kevin A. Myers,
- Sunanda Dhar,
- David Ferguson,
- Robert C. Bast,
- Anil K. Sood,
- Frank von Delft,
- Ahmed Ashour Ahmed
Affiliations
- Yiyan Zheng
- Ovarian Cancer Cell Laboratory, Weatherall Institute of Molecular Medicine, University of Oxford
- Ritika Sethi
- Structural Genomics Consortium, Nuffield Department of Medicine, University of Oxford
- Lingegowda S. Mangala
- Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center
- Charlotte Taylor
- Ovarian Cancer Cell Laboratory, Weatherall Institute of Molecular Medicine, University of Oxford
- Juliet Goldsmith
- Ovarian Cancer Cell Laboratory, Weatherall Institute of Molecular Medicine, University of Oxford
- Ming Wang
- Ovarian Cancer Cell Laboratory, Weatherall Institute of Molecular Medicine, University of Oxford
- Kenta Masuda
- Ovarian Cancer Cell Laboratory, Weatherall Institute of Molecular Medicine, University of Oxford
- Mohammad Karaminejadranjbar
- Ovarian Cancer Cell Laboratory, Weatherall Institute of Molecular Medicine, University of Oxford
- David Mannion
- Ovarian Cancer Cell Laboratory, Weatherall Institute of Molecular Medicine, University of Oxford
- Fabrizio Miranda
- Ovarian Cancer Cell Laboratory, Weatherall Institute of Molecular Medicine, University of Oxford
- Sandra Herrero-Gonzalez
- Ovarian Cancer Cell Laboratory, Weatherall Institute of Molecular Medicine, University of Oxford
- Karin Hellner
- Ovarian Cancer Cell Laboratory, Weatherall Institute of Molecular Medicine, University of Oxford
- Fiona Chen
- Ovarian Cancer Cell Laboratory, Weatherall Institute of Molecular Medicine, University of Oxford
- Abdulkhaliq Alsaadi
- Ovarian Cancer Cell Laboratory, Weatherall Institute of Molecular Medicine, University of Oxford
- Ashwag Albukhari
- Ovarian Cancer Cell Laboratory, Weatherall Institute of Molecular Medicine, University of Oxford
- Donatien Chedom Fotso
- Ovarian Cancer Cell Laboratory, Weatherall Institute of Molecular Medicine, University of Oxford
- Christopher Yau
- Wellcome Trust Centre for Human Genetics and NIHR Biomedical Research Centre
- Dahai Jiang
- Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center
- Sunila Pradeep
- Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center
- Cristian Rodriguez-Aguayo
- Center for RNAi and Non-Coding RNA, The University of Texas MD Anderson Cancer Center
- Gabriel Lopez-Berestein
- Center for RNAi and Non-Coding RNA, The University of Texas MD Anderson Cancer Center
- Stefan Knapp
- Structural Genomics Consortium, Nuffield Department of Medicine, University of Oxford
- Nathanael S. Gray
- Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School
- Leticia Campo
- Department of Oncology, University of Oxford
- Kevin A. Myers
- Department of Oncology, University of Oxford
- Sunanda Dhar
- Department of Histopathology, Oxford University Hospitals
- David Ferguson
- Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine University of Oxford, Oxford University Hospitals
- Robert C. Bast
- Department of Experimental Therapeutics, University of Texas MD Anderson Cancer Center
- Anil K. Sood
- Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center
- Frank von Delft
- Structural Genomics Consortium, Nuffield Department of Medicine, University of Oxford
- Ahmed Ashour Ahmed
- Ovarian Cancer Cell Laboratory, Weatherall Institute of Molecular Medicine, University of Oxford
- DOI
- https://doi.org/10.1038/s41467-017-02811-7
- Journal volume & issue
-
Vol. 9,
no. 1
pp. 1 – 12
Abstract
Some anticancer drugs target cell microtubules inhibiting mitosis and cell division. Here, the authors show that CRMP2 induces microtubule bundling and that this activity is regulated by the FER kinase, thus providing a rationale for targeting FER in combination with microtubule-targeting drugs.
